Children born with NAXD deficiency—a genetic disorder that can be rapidly fatal—may have a better future with early, high-dose vitamin B3 (niacin), according to a new study. The research indicates that niacin can slow or interrupt the deterioration triggered by common infections.
Led by the Murdoch Children’s Research Institute (MCRI) in collaboration with the Luxembourg Centre for Systems Biomedicine (LCSB), the team expanded scientific understanding of how NAXD deficiency behaves in real patients. Their findings suggest clinicians should treat the condition as potentially manageable rather than inevitably progressive.
NAXD deficiency results from harmful variants in the NAXD gene, which normally supports cellular energy production. When the gene is impaired, energy-dependent pathways become vulnerable—especially during physiological stress—turning routine illnesses into dangerous medical emergencies.
In the study, nine additional cases were identified, broadening the known clinical spectrum. Symptoms were not limited to the nervous system; researchers also observed cardiac involvement and developmental issues, including features apparent before birth.
A key insight was treatment response. Four children who received high-dose niacin survived febrile infections that, based on prior experience, often lead to severe complications or death. Two patients showed disease onset following COVID-19, underscoring how viral infections can act as triggers.
The paper also connects genetic differences to distinct clinical trajectories. One group displayed a more typical pattern of neurological decline—seizures and developmental delay after illness. Another group developed serious heart complications, while a severe prenatal neurodegeneration case resulted in stillbirth.
Together, these observations highlight two practical needs: earlier recognition and rapid intervention when symptoms emerge after infection. The authors note that updated diagnostic strategies may help identify patients with “non-typical” presentations.
While longer-term outcomes with sustained niacin therapy remain to be established, the study’s results provide a strong rationale for considering NAXD deficiency a treatable disorder. The team is also exploring other medicines that may enhance cellular energy pathways, potentially offering alternative options.
Finally, the study reinforces preventive care. Because infections can precipitate crises, staying up to date with vaccinations may be especially important for children living with NAXD deficiency.
Subject of Research: People
Article Title: NAXD Deficiency: Heterogeneous Phenotypes and Positive Response to Niacin Treatment
News Publication Date: 12-Jul-2026
Web References: https://onlinelibrary.wiley.com/doi/10.1002/jimd.70217 ; http://dx.doi.org/10.1002/jimd.70217
References: 10.1002/jimd.70217
Image Credits: Not provided
Keywords: NAXD deficiency, vitamin B3, niacin therapy, rare genetic disorder, cellular energy pathways, pediatric medicine, metabolic disorders, neurological deterioration, cardiac complications, infection-triggered crises
